In trans T cell tolerance diminishes autoantibody responses and exacerbates experimental allergic encephalomyelitis

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1508-1516

  Bell, J Jeremiah ^a,b   Divekar, Rohit D ^a   Ellis, Jason S ^a   Cascio, Jason A ^a   Haymaker, Cara L ^a   Jain, Renu ^a   Tartar, Danielle M ^a   Hoeman, Christine M ^a   Hardaway, John C ^a   Zaghouani, Habib ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN MYELIN OLIGODENDROCYTE GLYCOPROTEIN AGGREGATE; IMMUNOGLOBULIN PROTEOLIPID PROTEIN 1 AGGREGATE; IMMUNOGLOBULIN PROTEOLIPID PROTEIN LR AGGREGATE; IMMUNOMODULATING AGENT; INTERLEUKIN 5; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEOLIPID PROTEIN; UNCLASSIFIED DRUG; EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN; MYELIN ASSOCIATED GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); NERVE PROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; PEPTIDE; PEPTIDE FRAGMENT; PLP PROTEIN, MOUSE; PROTEOLIPID PROTEIN 139 151; PROTEOLIPID PROTEIN 139-151;

ALLELE; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CELL STIMULATION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENETIC POLYMORPHISM; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; AUTOANTIBODIES; CHIMERA; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES; GLYCOPROTEINS; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULINS; INTERLEUKIN-5; MICE; MICE, MUTANT STRAINS; MYELIN PROTEOLIPID PROTEIN; MYELIN-ASSOCIATED GLYCOPROTEIN; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; T-LYMPHOCYTES;

EID: 40749117207     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1508     Document Type: Article

References (29)

1. Sospedra, M., and R. Martin. 2005. Antigen specific therapy in multiple sclerosis. Int. Rev. Immunol. 24: 393-413.
2. Fontoura, P., H. Garren, and L. Steinman. 2005. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int. Rev. Immunol. 24: 415-446.
3. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, L. Steinman, and the Altered Peptide Ligand in Relapsing MS Study Group. 2000. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat. Med. 6: 1176-1182.
4. Legge, K. L., B. Min, J. J. Bell, J. C. Caprio, L. Li, R. K. Gregg, and H. Zaghouani. 2000. Coupling of peripheral tolerance to endogenous interleukin 10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis. J. Exp. Med. 191: 2039-2052.
5. Legge, K. L., R. K. Gregg, R. Maldonaldo-Lopez, L. Li, J. C. Caprio, M. Moser, and H. Zaghouani. 2002. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196: 217-227.
6. Gregg, R. K., R. Jain, S. J. Schoenleber, R. Divekar, J. J. Bell, H.-H. Lee, P. Yu, and H. Zaghouani. 2004. A sudden decline in active membrane-bound TGFβ impairs both T regulatory cell function and protection against autoimmune diabetes. J. Immunol. 173: 7308-7316.
7. Gregg, R. K., J. J. Bell, H.-H. Lee, R. Jain, S. J. Schoenleber, R. Divekar, and H. Zaghouani. 2005. IL-10 diminishes CTLA-4 expression on islet-resident T cells and sustains their activation rather than tolerance. J. Immunol. 174: 662-670.
8. Legge, K. L., J. J. Bell, L. Li, R. Gregg, J. C. Caprio, and H. Zaghouani. 2001. Multi-modal antigen specific therapy for autoimmunity. Int. Rev. Immunol. 20: 593-611.
9. Tuohy, V. K., Z. Lu, R. A. Sobel, R. A. Laursen, and M. B. Lees. 1989. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142: 1523-1527.
10. Kerlero de Rosbo, N., I. Mendel, and A. Ben-Nun. 1995. Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur. J. Immunol. 25: 985-993.
11. Greer, J. M., V. K. Kuchroo, R. A. Sobel, and M. B. Lees. 1992. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. J. Immunol. 149: 783-788.
12. Brocke, S., K. Gijbels, M. Allegretta, I. Ferber, C. Piercy, T. Blankenstein, R. Martin, U. Utz, N. Karin, D. Mitchell, et al. 1996. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 379: 343-346.
13. Kuchroo, V. K., J. M. Greer, D. Kaul, G. Ishioka, A. Franco, A. Sette, R. A. Sobel, and M. B. Lees. 1994. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153: 3326-3336.
14. Legge, K. L., B. Min, N. T. Potter, and H. Zaghouani. 1997. Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing. J. Exp. Med. 185: 1043-1053.
15. Pack, C. D., A. E. Cestra, B. Min, K. L. Legge, L. Li, J. C. Caprio-Young, J. J. Bell, R. K. Gregg, and H. Zaghouani. 2001. Neonatal exposure to antigen primes the immune system to develop responses in various lymphoid organs and promotes bystander regulation of diverse T cell specificities. J. Immunol. 167: 4187-4195.
16. Min, B., K. L. Legge, C. Pack, and H. Zaghouani. 1998. Neonatal exposure to a self-peptide immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin-4 lymph node deviation and interferon γ mediated splenic anergy. J. Exp. Med. 188: 2007-2017.
17. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
18. + T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J. Immunol. 166: 7579-7587.
19. + T cell responses during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 35: 76-85.
20. Lehmann, P. V., T. Forsthuber, A. Miller, and E. E. Sercarz. 1992. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358: 155-157.
21. Yu, M., J. M. Johnson, and V. K. Tuohy. 1996. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183: 1777-1788.
22. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182: 75-85.
23. Schluesener, H. J., R. A. Sobel, C. Linington, and H. L. Weiner. 1987. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J. Immunol. 139: 4016-4021.
24. Genain, C. P., M. H. Nguyen, N. L. Letvin, R. Pearl, R. L. Davis, M. Adelman, M. Lees, C. Linington, and S. L. Hauser. 1995. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96: 2966-2974.
25. Weir, C., C. C. A. Bernard, and B. T. Bäckström. 2003. IL-5-deficient mice are susceptible to experimental autoimmune encephalomyelitis. Int. Immunol. 15: 1283-1289.
26. Von Budingen, H. C., S. L. Hauser, J. C. Ouallet, N. Tanuma, T. Menge, and C. P. Genain. 2002. Epitope recognition on the myelin oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination. Eur. J. Immunol. 34: 2072-2083.
27. O'Connor, K. C., K. A. McLaughlin, P. L. De Jager, T. Chitnis, E. Bettelli, C. Xu, W. H. Robinson, S. V. Cherry, A. Bar-Or, B. Banwell, et al. 2006. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 13: 211-217.
28. b mice. J. Immunol. 171: 455-461.
29. Zamvil, S., P. Nelson, D. Mitchell, R. Knobler, R. Fritz, and L. Steinman. 1985. Encephalitogenic T cell clones specific for myelin basic protein: an unusual bias in antigen presentation. J. Exp. Med. 162: 2107-2124.